UPDATE: Morgan Stanley Maintains Overweight on McKesson Corp, Lowers PT to $180.00 from $190.00

In a report published Tuesday, Morgan Stanley analyst Julie Murphy maintained an Overweight rating on McKesson Corporation MCK, lowering its price target to $180.00 from $190.00. According to the report, the analysts outline three potential scenarios and related accretion that could unfold following MCK's failure to tender 75 percent of CLSG shares: -”Establishing new JV with RAD / WMT and/or Celesio. The opportunity to gain share of customers' generic wallet represents a core part of our MCK investment thesis.” -”Share buybacks. We estimate MCK had ~$3.5 billion in cash at the end of the December quarter of which $1.5 billion is ex US.” -”Another go at Celesio. According to a MCK filing, the company must wait 4-days following the failure of a tender to place another offer for shares if it chooses to.” The report further asserted that they now model FY14/FY15 EPS of $8.76/$10.47 down from prior estimates of $8.69/$11.03 and above cons' $8.62/$10.39. Their updated model assumes $2.5B ASR in the March quarter, but no benefit from potential JV or an acquisition. MCK closed Monday at $167.14.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorReiterationAnalyst RatingsHealth CareHealth Care DistributorsJulie MurphyMorgan Stanley
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!